ANDA 76198, held by Barr. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 76198 (Balziva-21), held by Barr, was first approved by FDA on Apr 22, 2004, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Balziva-210.035MG;0.4MG ยท tablet;oral-21 | Ethinyl Estradiol; Norethindrone | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters